Reminder: Complimentary Registration Available to Corporate-Sponsored Program on Whole Blood-Derived Platelets

Currently, more than 94% of the platelet supply in the United States is collected by apheresis.¹ With the decline in the apheresis donor population and continued post-pandemic blood supply challenges, whole blood-derived platelets could boost the platelet supply.²

In an upcoming Science and Innovation Forum, presented by Terumo Blood and Cell Technologies, Gustaaf de Ridder, MD, transfusion medicine director at Geisinger Medical Center; and Mark H. Yazer, MD, professor of pathology at the University of Pennsylvania, will share their perspectives on the merits of whole blood-derived platelets. Anna Razatos, PhD, global scientific marketing at Terumo, will moderate the discussion.

The program will take place 2-3 p.m. ET on Thursday, June 22. This Science and Innovation Forum is complimentary to all, but registration is required.

¹Jones et al. Has the trend of declining blood transfusions in the United States ended? Findings of the 2019 National Blood Collection and Utilization Survey. Transfusion. 2021;61:S1–S10

²Stubbs et al. The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages. Transfusion. 2021;61:303-312J